Prime Medicine appoints Svetlana Makhni as CFO effective April 16, 2026

Prime Medicine, Inc.

Svetlana Makhni named CFO; base salary $495K, sign-on bonus $40K, target bonus 40%.
Granted option to purchase 800K shares (time-based vesting over 4 years) and 100K milestone-based option.
Allan Reine steps down as principal financial officer but remains CEO.
Makhni has 20+ years biotech/healthcare CFO and investment banking experience.

item 5.02item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Svetlana Makhni

Chief Financial Officer

Prime Medicine, Inc.

Effective: 2026-04-16
Filed: Apr 16, 2026 23:59 UTC

On April 7, 2026, the Board of Directors (the “Board”) of Prime Medicine, Inc. (the “Company”) appointed Svetlana Makhni as the Chief Financial Officer and the principal financial officer of the Company effective as of April 16, 2026.

Source: SEC EDGAR

accession 0001628280-26-025372

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.